Dr John Koo, of the Phototherapy and Skin Treatment Clinic at the University of California San Francisco, gave an update on new data on oral therapeutics in psoriasis .
Apremilast appears to have lower efficacy than some biologic agents. However, its ease of administration as an oral agent, coupled with a mild side-effect profile, make it an attractive option for many psoriasis patients.
A poster presented at the annual meeting of the European Academy of Dermatology and Veneorology (EADV) in Geneva provided more insight into the mode of action of this small molecule: it assessed the influence of apremilast on different cytokines compared to placebo .
Data came from the ESTEEM 2 trial, which confirmed the therapeutic concept that apremilast works as a cytokine modulator. It has a distinct effect on the proinflammatory cytokines IL-17A, IL-17F and IL-22, but lowers TNF-α to only a minimal amount. “I think it is therefore a good idea to combine apremilast ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« A glimpse into the future Next Article
Melanoma incidence continues to rise in Europe »
Table of Contents: AAD 2018
Psoriasis: an update
What's hot in atopic dermatitis
Pearls of the posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.